Stocks · News reference

JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $950

Oct 6, 2026, 2:55 PMBenzinga Newsdesk

JP Morgan analyst Chris Schott maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $900 to $950.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 7, 2026, 2:55 PMBenzinga Newsdesk
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $779
Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $758 to $779.
REGN
BenzingaOct 6, 2026, 11:58 AMBenzinga Newsdesk
Regeneron Pharmaceuticals, Sanofi Amend License, Collaboration Agreement To Jointly Develop, Commercialize Four New Regeneron-Invented Antibodies; Regeneron Anticipates Pre-Tax Acquired In-Process Research And Development Charge Of ~$22M
https://www.sec.gov/ix?doc=/Archives/edgar/data/872589/000110465926113895/tm2627077d1_8k.htm
REGN SNY
SEC EDGAROct 6, 2026, 11:51 AMSEC EDGAR
8-K filing — REGENERON PHARMACEUTICALS, INC. (REGN)
Filed: 2026-10-06 AccNo: 0001104659-26-113895 Size: 206 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events
REGN